AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32644149 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36371700 — intervention group
Group type: EXPERIMENTAL
Intervention: iBM (intensified behavioral modification)
Number of subjects: 120
Study 36371700 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT1 (iBM + additional exercise from 0 to 3 months)
Number of subjects: 120
Study 36371700 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT2 (iBM + additional exercise from 6 to 9 months)
Number of subjects: 120
Study 36371700 — intervention group
Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 120
Study 33842981 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based vestibular rehabilitation
Number of subjects: 65
Study 33842981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 32899067 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants
Number of subjects: 0
Study 32899067 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 0
Study 35748757 — intervention group
Group type: EXPERIMENTAL
Intervention: External concurrent occipital and trigeminal neurostimulation
Number of subjects: 131
Study 35748757 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 131
Study 34004177 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study 34004177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 36316617 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor (CGF) membrane
Number of subjects: 22
Study 36316617 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Gide collagen membrane
Number of subjects: 22
Study 32744862 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061
Study 32744862 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 32744862 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061
Study 32744862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Canakinumab groups
Number of subjects: 10061
Study 32744862 — intervention group
Group type: COMPARATOR
Intervention: N/A (Placebo)
Number of subjects: 10061
Study 34864158 — intervention group
Group type: COMPARATOR
Intervention: DAA alone (group 1)
Number of subjects: 56
Study 34864158 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA plus 12 weeks of entecavir (group 2)
Number of subjects: 56
Study 34864158 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA plus 24 weeks of entecavir (group 3)
Number of subjects: 56
Study 34864158 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 33798309 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple needling combined with thermo-electroacupuncture at Huantiao (GB 30)
Number of subjects: 56
Study 33798309 — intervention group
Group type: COMPARATOR
Intervention: Triple needling combined with electroacupuncture at Huantiao (GB 30)
Number of subjects: 56
Study 33618977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable MM lens 1
Number of subjects: 20
Study 33618977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disposable MM lens 2
Number of subjects: 20
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastidious Anaerobe Agar (FAA) with incubation for 16-20 hours
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastidious Anaerobe Agar (FAA) with incubation for 24 hours
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastidious Anaerobe Agar (FAA) with incubation at 35°C
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastidious Anaerobe Agar (FAA) from different manufacturers
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin with prolonged incubation (40-44 hours)
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 170
Study 33813129 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 170
Study 32867053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 for 90 days
Number of subjects: 40
Study 32867053 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 40
Study 32867053 — intervention group
Group type: EXPERIMENTAL
Intervention: LL‐37 neutralizing antibody
Number of subjects: 40
Study 32867053 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer–fall season
Number of subjects: 40
Study 35345925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn tablets 20 mg/day)
Number of subjects: 144
Study 35345925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 33017836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg (single dose)
Number of subjects: 38
Study 33017836 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg (single dose)
Number of subjects: 38
Study 33017836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (weekly administration)
Number of subjects: 38
Study 33017836 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (weekly administration)
Number of subjects: 38
Study 32017677 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSVΔ-ZEBOV-GP Ebola vaccine
Number of subjects: 84
Study 32017677 — intervention group
Group type: COMPARATOR
Intervention: Deferred vaccination (unvaccinated group)
Number of subjects: 84
Study 32017677 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk for vaccine viremia (conception before or <14 days after vaccination)
Number of subjects: 84
Study 32017677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower risk for vaccine viremia (conception >15 days after vaccination)
Number of subjects: 84
Study 32017677 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-born infants examined
Number of subjects: 84
Study 34479938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC) 4g and prothrombin complex concentrate (PCC) 2000 IU
Number of subjects: 350
Study 34479938 — intervention group
Group type: COMPARATOR
Intervention: Plasma 4 U
Number of subjects: 350
Study 32297653 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml ropivacaine 0.75%
Number of subjects: 25
Study 34250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 31
Study 34250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 31
Study 34250846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 33827915 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) beyond 6.5 hours
Number of subjects: 3264
Study 33827915 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) within 6.5 hours
Number of subjects: 3264
Study 32053101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg generic sofosbuvir in fasted state
Number of subjects: 12
Study 32053101 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg generic sofosbuvir in fasted state
Number of subjects: 12
Study 32053101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg daily for 8 days
Number of subjects: 12
Study 32053101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg generic sofosbuvir after a high-fat meal
Number of subjects: 12
Study 32053101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg generic sofosbuvir
Number of subjects: 12
Study 34781421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2.0 μg/kg, i.m.) in 2.5 mL saline
Number of subjects: 100
Study 34781421 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo, i.m.) 2.5 mL
Number of subjects: 100
Study 35142011 — intervention group
Group type: EXPERIMENTAL
Intervention: DWJ211 0.5%
Number of subjects: 136
Study 35142011 — intervention group
Group type: EXPERIMENTAL
Intervention: DWJ211 1%
Number of subjects: 136
Study 35142011 — intervention group
Group type: EXPERIMENTAL
Intervention: DWJ211 2%
Number of subjects: 136
Study 35142011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 32979188 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz cerebellar vermis rTMS
Number of subjects: 25
Study 32979188 — intervention group
Group type: COMPARATOR
Intervention: Unilateral rTMS
Number of subjects: 25
Study 32979188 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 25
Study 34992202 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 331
Study 34992202 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 331
Study 33745079 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 278
Study 33745079 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 278
Study 33745079 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (prior sorafenib < 3 months)
Number of subjects: 278
Study 33745079 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib (prior sorafenib < 3 months)
Number of subjects: 278
Study 33745079 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (prior sorafenib 3 to < 6 months)
Number of subjects: 278
Study 33745079 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib (prior sorafenib 3 to < 6 months)
Number of subjects: 278
Study 33745079 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (prior sorafenib ≥ 6 months)
Number of subjects: 278
Study 33745079 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib (prior sorafenib ≥ 6 months)
Number of subjects: 278
Study 34265211 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (80% of 1RM)
Number of subjects: 24
Study 34265211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance training (40% of 1RM)
Number of subjects: 24
Study 33507266 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN3048 plus REGN3051
Number of subjects: 36
Study 33507266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33191060 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid (including standard information, quantitative information on outcomes of cataract surgery, and a value clarification exercise)
Number of subjects: 773
Study 33191060 — intervention group
Group type: COMPARATOR
Intervention: Control booklet (including standard information)
Number of subjects: 773
Study 34218726 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 150 mg bid
Number of subjects: 456
Study 34218726 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 300 mg bid
Number of subjects: 456
Study 34218726 — intervention group
Group type: EXPERIMENTAL
Intervention: Reldesemtiv 450 mg bid
Number of subjects: 456
Study 34218726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 34218726 — intervention group
Group type: EXPERIMENTAL
Intervention: All reldesemtiv doses combined
Number of subjects: 456
Study 35988059 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol capsule (0.75 μg) under fasting conditions
Number of subjects: 55
Study 35988059 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol capsule (0.75 μg) under fed conditions
Number of subjects: 55
Study 35988059 — intervention group
Group type: COMPARATOR
Intervention: Eldecalcitol capsule (0.75 μg)
Number of subjects: 55
Study 34886619 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy with catheterization and balloon dilatation of the Eustachian tube
Number of subjects: 100
Study 34886619 — intervention group
Group type: COMPARATOR
Intervention: Tympanostomy and catheterization
Number of subjects: 100
Study 35022080 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-endorsed narrative SMS intervention
Number of subjects: 1400
Study 35022080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 1400
Study 32538182 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of vitamin D (28 IU/kg)
Number of subjects: 173
Study 32538182 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing of vitamin D (2000 IU/day)
Number of subjects: 173
Study 32538182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (weight-based and fixed dosing)
Number of subjects: 173
Study 32538182 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of vitamin D
Number of subjects: 173
Study 36235651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual supplementation of multi-strain probiotic (B. lactis Bi‐07, L. paracasei Lpc‐37, L. acidophilus NCFM, B. lactis Bl‐04) and omega-3 supplements for eight weeks
Number of subjects: 76
Study 36235651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual supplementation of multi-strain probiotic and omega-3 supplements
Number of subjects: 76
Study 36235651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 33121627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T1)
Number of subjects: 60
Study 33121627 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (T0)
Number of subjects: 60
Study 33121627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Simmental bull seminal plasma protein per mL egg yolk‐citrate extender (T2)
Number of subjects: 60
Study 33634843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram intervention
Number of subjects: 221
Study 33634843 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 221
Study 32633896 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous application of gaseous CO2 (20 therapies with medical-grade CO2 gas)
Number of subjects: 57
Study 32633896 — intervention group
Group type: COMPARATOR
Intervention: Control group (same treatment with air)
Number of subjects: 57
Study 32633896 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous application of gaseous CO2
Number of subjects: 57
Study 35579360 — intervention group
Group type: EXPERIMENTAL
Intervention: SVATS (subxiphoid uniportal video-assisted thoracoscopic surgery)
Number of subjects: 262
Study 35579360 — intervention group
Group type: COMPARATOR
Intervention: UVATS (uniportal intercostal video-assisted thoracoscopic surgery)
Number of subjects: 262
Study 33478324 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% iodiconazole cream (0.4 g)
Number of subjects: 30
Study 33478324 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% iodiconazole cream (0.4 g)
Number of subjects: 30
Study 33478324 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% iodiconazole cream (0.4 g)
Number of subjects: 30
Study 32505485 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst protocols (iTBS) rTMS (50 Hz, 900 pulses, 20 daily sessions over 4 weeks)
Number of subjects: 60
Study 32505485 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 60
Study 35439754 — intervention group
Group type: EXPERIMENTAL
Intervention: OPF‐105 (novel all‐in‐one peripheral parenteral nutrition solution)
Number of subjects: 99
Study 35439754 — intervention group
Group type: COMPARATOR
Intervention: BFL (combination of a commercially available PPN solution and fat emulsion)
Number of subjects: 99
Study 35439754 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OPF‐105 and BFL
Number of subjects: 99
Study 34628077 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention based on cognitive-behavioral therapy delivered by Medical Assistants in primary care.
Number of subjects: 0
Study 34628077 — intervention group
Group type: COMPARATOR
Intervention: Routine referral to mental health services (Control).
Number of subjects: 0
Study 32705831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteretic acupuncture
Number of subjects: 72
Study 32705831 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib capsules (200 mg once daily)
Number of subjects: 72
Study 35268070 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐NCS diet (50‐100 mg/day NCS)
Number of subjects: 0
Study 35268070 — intervention group
Group type: COMPARATOR
Intervention: NCS‐f diet (less than 10 mg/day NCS)
Number of subjects: 0
Study 32034557 — intervention group
Group type: EXPERIMENTAL
Intervention: External attentional feedback
Number of subjects: 96
Study 32034557 — intervention group
Group type: EXPERIMENTAL
Intervention: External attentional instruction
Number of subjects: 96
Study 32034557 — intervention group
Group type: EXPERIMENTAL
Intervention: External feedback
Number of subjects: 96
Study 32034557 — intervention group
Group type: COMPARATOR
Intervention: Internal attentional feedback
Number of subjects: 96
Study 32034557 — intervention group
Group type: COMPARATOR
Intervention: Internal attentional instruction
Number of subjects: 96
Study 35771216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (KE)
Number of subjects: 11
Study 35771216 — intervention group
Group type: COMPARATOR
Intervention: Control drink (CON)
Number of subjects: 11
Study 35771216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (KE)
Number of subjects: 11
Study 33559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 232
Study 33559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 232
Study 33559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustion
Number of subjects: 232
Study 33559131 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 232
Study 32627073 — intervention group
Group type: EXPERIMENTAL
Intervention: INTP24
Number of subjects: 117
Study 33349963 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% eccentric contractions (10%EC)
Number of subjects: 24
Study 33349963 — intervention group
Group type: EXPERIMENTAL
Intervention: Two maximal voluntary isometric contractions at a long muscle length (2MVIC)
Number of subjects: 24
Study 33349963 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT-1st) performing two bouts of maximal eccentric contractions (MaxEC)
Number of subjects: 24
Study 33349963 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT-2nd) performing two bouts of MaxEC
Number of subjects: 24
Study 33020090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led model
Number of subjects: 693
Study 33020090 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted model
Number of subjects: 693
Study 33020090 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 693
Study 34766812 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pandemic teacher stress levels
Number of subjects: 639
Study 34766812 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher confidence in managing student behaviors
Number of subjects: 639
Study 34766812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-COVID-19 school-level factors
Number of subjects: 639
Study 32738502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over speech motor cortex
Number of subjects: 0
Study 32738502 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 35700073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 102
Study 35700073 — intervention group
Group type: COMPARATOR
Intervention: Closed Reduction and Internal Fixation (IF)
Number of subjects: 102
Study 34636309 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-assisted rehabilitation cycling
Number of subjects: 66
Study 34636309 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation cycling without stimulation
Number of subjects: 66
Study 32279349 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term patch test protocol with an application period of 20 minutes
Number of subjects: 0
Study 32279349 — intervention group
Group type: COMPARATOR
Intervention: Patch test results
Number of subjects: 0
Study 34743533 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 70
Study 34743533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33350361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CECT7263 (2×10^8 cfu/day)
Number of subjects: 150
Study 33350361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lactobacillus fermentum CECT5716 and Bifidobacterium breve CECT7263 (1×10^8 cfu/day per strain)
Number of subjects: 150
Study 33350361 — intervention group
Group type: COMPARATOR
Intervention: Simethicone (80 mg/day)
Number of subjects: 150
Study 36267269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine postconditioning (DPOC) via intravenous administration at 0.6 μg kg−1 for 10 min immediately after unclamping the renal artery
Number of subjects: 77
Study 36267269 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline administered under the same protocol as DPOC
Number of subjects: 77
Study 36267269 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 77
Study 36389295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless anesthesia (SV group)
Number of subjects: 60
Study 36389295 — intervention group
Group type: COMPARATOR
Intervention: Intubated anesthesia (MV group)
Number of subjects: 60
Study 32761174 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth with 2 home visits
Number of subjects: 2626
Study 32761174 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth with no home visits
Number of subjects: 2626
Study 32761174 — intervention group
Group type: COMPARATOR
Intervention: Standard message
Number of subjects: 2626
Study 35467064 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX‐CLG (1875/125 mg of AMX‐CL orally 1–2 h prior to surgery)
Number of subjects: 40
Study 35467064 — intervention group
Group type: EXPERIMENTAL
Intervention: AMXG (2 g of amoxicillin orally)
Number of subjects: 40
Study 35467064 — intervention group
Group type: COMPARATOR
Intervention: CG (no prophylaxis)
Number of subjects: 40